UK-based Cancer Research Technology (CRT) has extended its collaboration with US pharmaceutical company Merck to discover new cancer drugs targeting the Hippo pathway.

The completion of the deal between the two parties follows a successful one-year target validation and drug discovery feasibility collaboration between CRT’s Discovery Laboratories (CRT-DL) in London, UK, and Cambridge and Merck at Darmstadt, Germany.

The alliance has helped develop an enhanced understanding of the role of the Hippo pathway in cancer and the best drug for the key targets.

CRT chief executive Dr Iain Foulkes said: “The extension and expansion of this alliance showcases the success of CRT’s Discovery Laboratories drug discovery approach in moving forward exciting new approaches to cancer therapy.

"We’re now focused on developing these early projects for the benefit of cancer patients.”

“We’ve brought together leading academics in the field and industry to build on world-class research, and we’re now focused on developing these early projects for the benefit of cancer patients.”

The Hippo pathway in healthy cells regulates cell size, thereby controlling the growth of tissues during development and regeneration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, abnormal activation of proteins controlled by the Hippo pathway can result in the development of a wide range of cancers.

The current partnership between Merck and CRT entirely focuses on the discovery of cancer drugs to identify molecules that would be taken into preclinical studies and clinical trials.

From the deal, CRT will receive royalties and milestone payments to be invested into the research conducted by Cancer Research UK.


Image: CRT and Merck collaborate to discover new cancer drugs targeting Hippo pathway. Photo: courtesy of Cancer Research UK.